• Mashup Score: 2
    The role of isatuximab in the management of MM - 4 year(s) ago

    Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, discusses the role of isatuximab in the management of multiple myeloma (MM)….

    Source: VJHemOnc
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of VJHemOnc
      VJHemOnc

      VIDEO: The role of #Isatuximab in the management of #Myeloma: w/ @Mohty_EBMT of @HUEstParisien: https://t.co/N0HJTijAqx @VJHemOnc @EHA_Hematology #EHA25 #HemOnc #Oncoalert #EHAtrending #EHA25Virtual @OncoAlert #MMsm #ImmunoOnc

  • Mashup Score: 0
    JNCCN 360 - 4 year(s) ago

    By: Sarah Campen, PharmD Posted: Thursday, July 2, 2020 Induction with the four-drug combination of the monoclonal anti-CD38 antibody isatuximab plus carfilzomib, lenalidomide, and dexamethasone (KRd) appears to induce deep responses—including many patients with minimal residual disease negativity—in previously…

    Source: jnccn360.org
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of JNCCN
      JNCCN

      #EHA25: Adding #isatuximab to front-line standard of care in high-risk #multiplemyeloma: https://t.co/OCAozdvQuT #MMSM #JNCCN360 https://t.co/fDMKL6t4wx

  • Mashup Score: 1
    ICARIA-MM: isatuximab, pomalidomide & dexamethasone - 4 year(s) ago

    Meral Beksac, MD, of Ankara University, Ankara, Turkey, outlines the results of ICARIA-MM (NCT02990338), a study investing the utility of…

    Source: VJHemOnc
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of VJHemOnc
      VJHemOnc

      VIDEO: ICARIA-MM: #isatuximab, pomalidomide & dexamethasone w/ @mbeksac56 of @AnkaraUni: https://t.co/lw8UCsi41d @VJHemOnc @EHA_Hematology #EHA25 #HemOnc #MMsm #Oncoalert #EHAtrending #EHA25Virtual @OncoAlert #CTsm #ImmunoOnc

  • Mashup Score: 0
    IKEMA: kD vs isatuximab and kD in R/R myeloma - 4 year(s) ago

    Philippe Moreau, MD, Nantes University Hospital, Nantes, France, discusses the Phase III IKEMA study (NCT03275285), investigating isatuximab plus carfilzomib and…

    Source: VJHemOnc
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of VJHemOnc
      VJHemOnc

      #EHA25Virtual: New standard for R/R multiple myeloma? Philippe Moreau of @CHUnantes discusses the IKEMA study: kD vs #Isatuximab and kD in R/R #Myeloma 👉https://t.co/VU2M53cnhl👈 @VJHemOnc @EHA_Hematology #EHA25 #HemOnc #CTSM #Oncoalert #MMSM #ImmunoOnc #EHAtrending https://t.co/vbaRQV1lsr

  • Mashup Score: 1
    FDA approves Sarclisa regimen for adults with advanced multiple myeloma - 4 year(s) ago

    The FDA approved isatuximab-irfc in combination with pomalidomide and dexamethasone for the treatment of adults with multiple myeloma who received at least two previous therapies, including lenalidomide and a proteasome inhibitor.Isatuximab-irfc (Sarclisa, Sanofi) is an IV-administered monoclonal antibody that binds to the CD38 receptor on the surface of multiple myeloma cells.

    Source: bit.ly
    Categories: Hem/Onc News and Journals
    Tweet Tweets with this article
    • Profile photo of HemOncToday
      HemOncToday

      .@US_FDA approves Sarclisa in combination with pomalidomide and dexamethasone for adults with advanced multiple myeloma https://t.co/yfuHslNDvG @sanofi @SanofiUS #Isatuximab-irfc https://t.co/BMHVM9KZBK